Premier Fund Managers Ltd Grows Holdings in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Key Points

• Premier Fund Managers Ltd increased its stake in Lantheus Holdings, Inc. by 70.5%, bringing its total ownership to 11,010 shares valued at $1,058,000.
• Director Mary Anne Heino sold 26,066 shares for over $2 million, which represents a 7.56% reduction in her ownership.
• Lantheus has been rated as a "buy" by multiple brokerages, with an average price target of $131.20, even after reporting a decline in quarterly earnings compared to analysts' expectations.

Premier Fund Managers Ltd raised its position in Lantheus Holdings, Inc. (NASDAQ:LNTH - Free Report) by 70.5% in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,010 shares of the medical equipment provider's stock after acquiring an additional 4,552 shares during the period. Premier Fund Managers Ltd's holdings in Lantheus were worth $1,058,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Summit Securities Group LLC acquired a new stake in Lantheus in the fourth quarter valued at approximately $37,000. Signaturefd LLC raised its holdings in shares of Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider's stock worth $42,000 after buying an additional 116 shares during the last quarter. Hughes Financial Services LLC purchased a new position in shares of Lantheus in the first quarter worth $81,000. UMB Bank n.a. raised its holdings in shares of Lantheus by 68.2% in the first quarter. UMB Bank n.a. now owns 940 shares of the medical equipment provider's stock worth $92,000 after buying an additional 381 shares during the last quarter. Finally, Blue Trust Inc. raised its holdings in shares of Lantheus by 117.7% in the first quarter. Blue Trust Inc. now owns 1,171 shares of the medical equipment provider's stock worth $114,000 after buying an additional 633 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Lantheus news, Director Mary Anne Heino sold 26,066 shares of Lantheus stock in a transaction on Monday, June 2nd. The shares were sold at an average price of $76.83, for a total value of $2,002,650.78. Following the completion of the transaction, the director owned 318,650 shares of the company's stock, valued at approximately $24,481,879.50. The trade was a 7.56% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 1.50% of the company's stock.

Lantheus Stock Performance

Shares of Lantheus stock traded down $0.67 during trading on Friday, hitting $70.52. 622,546 shares of the company's stock were exchanged, compared to its average volume of 1,006,949. The company has a debt-to-equity ratio of 0.49, a quick ratio of 5.46 and a current ratio of 5.74. The business has a 50-day simple moving average of $77.71 and a 200-day simple moving average of $88.13. Lantheus Holdings, Inc. has a 52-week low of $69.12 and a 52-week high of $118.21. The stock has a market capitalization of $4.88 billion, a price-to-earnings ratio of 20.06 and a beta of 0.12.

Lantheus (NASDAQ:LNTH - Get Free Report) last issued its earnings results on Wednesday, May 7th. The medical equipment provider reported $1.53 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.64 by ($0.11). Lantheus had a return on equity of 36.99% and a net margin of 16.55%. The business had revenue of $372.76 million for the quarter, compared to analysts' expectations of $377.37 million. During the same period last year, the business earned $1.69 EPS. The company's revenue for the quarter was up .8% on a year-over-year basis. On average, research analysts forecast that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Analysts Set New Price Targets

LNTH has been the subject of a number of research analyst reports. Wall Street Zen raised shares of Lantheus from a "hold" rating to a "buy" rating in a report on Thursday, May 8th. William Blair reaffirmed a "market perform" rating on shares of Lantheus in a report on Wednesday, July 16th. B. Riley decreased their price target on shares of Lantheus from $122.00 to $109.00 and set a "buy" rating for the company in a report on Monday, June 23rd. Finally, Truist Financial decreased their price target on shares of Lantheus from $127.00 to $117.00 and set a "buy" rating for the company in a report on Thursday, May 8th. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company's stock. According to MarketBeat, Lantheus has an average rating of "Moderate Buy" and a consensus price target of $131.20.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.